Wsj
METIS News
Latest METIS market moves, ETF filings, on-chain events, and exchange news, tagged live by Stingray's news-impact pipeline.
Ask Stingray anything about METIS , press Enter to ask
Stingray take
Stingray take on METIS
Stingray's alert engine flagged no high-impact METIS news in the last 48 hours ; price is roughly flat over 24h (-2.5%). Quiet tape — usually a good window to catch up on on-chain trends without headline noise.
Signals are derived live from Stingray's news-impact pipeline — we tag every story with impact direction, confidence, and impact level the moment it lands.
Reuters
Metis TechBio in deal for experimental autoimmune drug worth up to $1.6 billion
Summary: Hong Kong-listed drug design tech firm Metis TechBio said on Tuesday it has granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to develop, manufacture and commercialise its experimental autoimmune drug MTS-128 in …
Read on Reuters → Wsj
WSJ: METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
Read on Wsj → Wsj
WSJ: METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
Read on Wsj → Wsj
WSJ: All Things Mobile Analytic, Inc. (OTCID:ATMH) Acquires Metis Technology S.p.A., Strengthening European Enterprise Capabilities
Read on Wsj → Bloomberg